Weekly Digest – March 2026 Weekly Digest – March 2026 13 March 2026: Alphamab Oncology announces IND application for innovative EGFR/HER3 dual payload bispecific ADC JSKN021 was officially accepted by CDE Alphamab Oncology has achieved a key regulatory milestone, as […]
Weekly Digest – March 2026 Weekly Digest – March 2026 20 March 2026: Alphamab Oncology announces the first patient dosed in a Phase 3 clinical study for triple-negative breast cancer of TROP2/HER3 bispecific ADC JSKN016 Alphamab Oncology has reached a […]
Weekly Digest – March 2026 Weekly Digest – March 2026 16 March 2026: CytomX’s Varsetatug Masetecan continues to demonstrate positive data supporting potential as a new treatment option in late-line colorectal cancer CytomX Therapeutics has strengthened its position in next-generation […]
Weekly Digest – March 2026 Weekly Digest – March 2026 17 March 2026: Alphamab Oncology announces the first patient dosed in a Phase 1 clinical study of PD-L1/VEGFR2 bispecific ADC JSKN027 Alphamab Oncology continues to expand its ADC pipeline, announcing […]
Weekly Digest – March 2026 Weekly Digest – March 2026 17 March 2026: Voro Therapeutics announced research collaboration with Daiichi Sankyo to advance PrimeBody™ technology for next-generation tumor-activated ADCs Voro Therapeutics has entered a strategic research collaboration with Daiichi Sankyo, […]
Weekly Digest – March 2026 Weekly Digest – March 2026 18 March 2026: Aptamer Group initiated Optimer radiopharmaceutical programme with Radiopharmium Ltd Aptamer Group plc has officially entered the fast-growing radiopharmaceutical space, launching a targeted programme built around its Optimer […]
